

November 9, 2020

Gongguan Tutamen Metalwork Co., LTD % Charles Shen
Official Correspondent
Manton Business and Technology Services
37 Winding Ridge
Oakland, New Jersey 07436

Re: K201431

Trade/Device Name: OGYILI TENS/NMES Stimulator

Regulation Number: 21 CFR 882.5890

Regulation Name: Transcutaneous Electrical Nerve Stimulator for Pain Relief

Regulatory Class: Class II Product Code: GZJ, IPF Dated: August 11, 2020 Received: August 13, 2020

Dear Charles Shen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

K201431 - Charles Shen Page 2

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Heather Dean, PhD
Assistant Director, Acute Injury Devices Team
DHT5B: Division of Neuromodulation
and Physical Medicine Devices
OHT5: Office of Neurological
and Physical Medicine Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2020 See PRA Statement below.

Over-The-Counter Use (21 CFR 801 Subpart C)

510(k) Number (if known)
K201431
Device Name
OGYILI TENS/NMES Stimulator
Indications for Use (Describe)
TENS function of the device is indicated for the following use:
Symptomatic relief and management of chronic (long-term), intractable pain and an adjunctive treatment in the
management of post-surgical pain and post-traumatic acute pain
NMES function of the device is indicated for the following use:
Relaxation of muscle spasms
Prevention or retardation of disuse atrophy
Increasing local blood circulation
Muscle re-education
• Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis
Maintaining or increasing range of motion
Tours of the (Oeles Long as hell)
Type of Use (Select one or both, as applicable)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

Prescription Use (Part 21 CFR 801 Subpart D)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary:

This summary of 510k safety and effectiveness information is being submitted In accordance with the requirements of 21CFR 807.92

5.1 Submitter & Foreign Manufacture Identification

Dongguan Tutamen Metalwork Co., LTD.

No.2, HuangGuoTang Rd, Shahu, Tangxia Town Dongguan, Guangdong Province, 523001 CHINA

Tel: (086) 769 87989845

Submitter's FDA Registration Number: N/A

5.2 Contact Person

Charles Shen Manton Business and Technology Services 37 Winding Rdg, Oakland, NJ 07436

Tel: 608-217-9358

Email: cyshen@aol.com

5.3 Date of Summary: November 02, 2020

5.4 Device Name:

Proprietary Name: OGYILI TENS/NMES Stimulator

Device Common Name: TENS/NMES Stimulator

Classification Regulation: 21 CFR882.5890

Class: Class 2
Panel: Neurology

Product Code: GZJ
Subsequent Product Code IPF
Prior FDA correspondence: None

5.5 Predicate Device Information:

The "OGYILI TENS/NMES Stimulator E01" described in this premarket notification is substantially equivalent to:

(1) K193275, "Nerve and Muscle Stimulator (model: XFT-2000)", Manufactured by "Shenzhen XFT Medical Limited"

Reference Device:

(2) K092990, "AMD 6605" manufactured by "Shenzhen Dongdixin Technology Co., Ltd."

(3) K162517, "Electronic Pulse Stimulator", Manufactured by "JKH Health Co., Ltd."

5.6 Device Description:

The OGYILI TENS/NMES Stimulator E01 is a 2 channel TENS/NMES stimulator device that is used to help reduce pain, with each channel being isolated from the other. The OGYILI TENS/NMES Stimulator is a programmable device that come equipped with 14 preset programs along with 14 user programs. The user programs are adjustable and can be changed to best help the patient at the doctor's recommendation and prescription settings. The program modes are preset programs that a clinician can conveniently choose from should they desire. This device has a special masking program to make the unwanted programs unavailable to the patients while locking the device in the needed relief setting. This way the patient does not receive the knowledge or ability to change the doctor's prescription settings without a clinician's consent. The OGYILI TENS/NMES Stimulator is programmed to default to program P- 14 which contains the most common setting.

The device gives the clinician ability to store frequencies or to choose from a set of many frequencies that allow quick and easy selection, for prescription of stimulation regimen that can be later stored in any of the many available memory slots. However once the program is set the patients does not have the ability to alter the program from what the doctor or licensed practitioner has deemed to be the most appropriate program for their patient's needs.

The OGYILI TENS/NMES Stimulator has the following specifications: There is pulse mode with a bi-phase rectangular pulse, the pulse frequency is 2Hz to 150Hz, the pulse width is 100-200 µs. The power supply is DC 3.7-volt lithium battery.

OGYILI TENS/NMES Stimulator package is comprised of the following items:

- One TENS/NMES unit powered by DC 3.7-volt lithium battery
- Two UL industry standard wires for electrodes conforming to FDA standards,
- Four standard commercially available round 100 (mm) self adhesive electrodes.
- One UL 110 battery rechargeable unit
- Instruction manual.
- Quick start instruction manual.
- Full package carrying case.

The device has physical dimensions of 92 x 60 x 18 mm, and weighs 90 grams with battery.

5.7 Indications for Use:

TENS function of the device is indicated for the following use:

Symptomatic relief and management of chronic (long-term), intractable pain and an adjunctive treatment in the management of post-surgical pain and post-traumatic acute pain

NMES function of the device is indicated for the following use:

- Relaxation of muscle spasms
- Prevention or retardation of disuse atrophy
- Increasing local blood circulation
- Muscle re-education
- Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis
- Maintaining or increasing range of motion

5.8 Performance Testing Summary:

Design control activities for this modification were performed and bench tests have been done. Those performance tests, risk management, and design verification tests provide demonstration that the device does not raise any new questions of safety and effectiveness.

The subject device conforms to the following standards:

- IEC 60601-2-10, Particular requirements for the basic safety and essential performance of nerve and muscle stimulators
- **IEC 60601-1-6.** General Requirements For Basic Safety And Essential Performance Collateral Standard: Usability
- **IEC60601-1**, Electrical safety;
- IEC60601-1-2, Electromagnetic compatibility
- **ISO 10993-1**, Biological evaluation of medical devices -- Part 1: Evaluation and testing within a risk management process

5.9 Technological Comparison with Predicate Device

Table 5.1 below shows similarities and differences of use, mechanism, and labeling between our device and the predicate devices.

Table 5.1: Comparison of Intended Use, Mechanism, and Labeling

Description	Subject Device	Primary Predicate Device (K193275)	Reference Device (K092990)	Remark
Product Code	GZJ	GZJ	GZJ	SE
Regulation Number	21 CFR882.5890	21 CFR882.5890	21 CFR882.5890	SE
Indication For Use	TENS function of the device is indicated for the following use: Symptomatic relief and management of chronic (long-term), intractable pain and an adjunctive treatment in the management of post-surgical pain and post-traumatic acute pain NMES function of the device is indicated for the following use: Relaxation of muscle spasms Prevention or retardation of disuse atrophy Increasing local blood circulation Muscle re-education Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis Maintaining or increasing range of motion	TENS[(Program 1~9, Program 15 (Frequency ≤ 5Hz or > 15Hz)]: XFT-2000 is used for temporary relief of pain associated with sore and aching muscles due to strain from exercise or normal household and work activities. XFT-2000 is also intended for the symptomatic relief and management of chronic, intractable pain and relief of pain associated with arthritis. NMES[(Program 10~14, Program 15(5Hz≤Frequency≤50Hz)]: XFT-2000 is used to stimulate healthy muscles in order to improve and facilitate muscle performance. To be used for the improvement of muscle tone and firmness, and for strengthening muscles in the arms, abdomen, legs, and buttocks. Not intended for use in any therapy or for the treatment of any medical conditions or diseases. Prescription Use: XFT-2000 is intended for the following use: - Relaxation of muscle spasms - Prevention or retardation of disuse atrophy - Increasing local blood circulation - Muscle re-education - Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis - Maintaining or increasing range of motion	TENS function of the device is indicated for the following use: Symptomatic relief and management of chronic (long-term), intractable pain and an adjunctive treatment in the management of post-surgical pain and post-traumatic acute pain NMES function of the device is indicated for the following use: • Relaxation of muscle spasms • Prevention or retardation of disuse atrophy • Increasing local blood circulation • Muscle re-education • Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis • Maintaining or increasing range of motion	SE

		- Adjunctive treatment in the management of post-surgical and post-traumatic acute pain		
Target Population	18 years and older	Adult Population	18 years and older	SE
Components	Control unit and electrode	Control unit and electrode	Control unit and electrode	SE
Contradictions	Never use your TENS/NMES on: Atrophied muscles. Muscles with spasms. Muscles associated with an impaired joint or limb. Muscles with undiagnosed pain. Never use the TENS/NMES when pregnant or if you think you are pregnant. Do not use your TENS/NMES With cardiac pacemakers, defibrillators, or other implanted metallic or electronic devices. Over or around the neck/carotid sinus. Over the neck, mouth or face. Over the carotid sinus nerves. Trans cerebrally (over the head). Over/around the eyes. Over the heart or chest. When there is a possibility to haemorrhage following acute trauma or fracture. After surgical procedures when muscle contraction may affect the healing process. On areas of skin which lack normal sensation	Not available as public information	Patients with pacemakers and heart conditions Patients with pacemakers and heart conditions TENS/NMES: should NOT use should NOT use Do NOT use stimulation over the carotids Do NOT use stimulation over the carotids sinus nerves, the larynx or throat muscles sinus nerves, the larynx or throat muscles Do NOT use stimulation transcerebrally. Do NOT use stimulation transcerebrally. Do NOT use on undiagnosed pain or until Do NOT use on undiagnosed pain or until I etiology is established.	Similar

The subject device are predicate devices are essentially identical in terms of use, and mechanism. They have minor different wording in the descriptions of contradictions, but the actual contents are very similar.

Table 5.2 shows similarities and differences of mechanism and design between our device and the predicate devices.

Table 5.2: Comparison of Mechanism and Design

Characteristic	Subject device (K201431)	Primary Predictive Device (K193275)	Reference Device (K092990)	Reference Device (K162517)	Remarks
Unit Name:	OGYILI TENS/NMES UNIT	XFT - 2000	AMD 6605	PL-029K12	
Manufacturer	Tutamen Metal Co., LTD	Shenzhen XFT Medical Limited	Shenzhen Dongdixin Technology Co., Ltd.	JKH USA LLC	
Power source	Use a Lithium-ion battery	DC4.5V, 3xAAA batteries; DC adaptor	Battery	Rechargeable or non- rechargeable battery	SE
a. Method of Line Current isolation	N/A battery operated	N/A battery operated	N/A battery operated	N/A battery Operated	SE
b. Patient Leakage current	N/A battery operated	N/A battery operated	N/A battery operated	N/A battery operated	SE
a. Normal condition	N/A battery operated	N/A battery operated	N/A battery operated	N/A battery operated	SE
b. Single Fault Condition	N/A battery operated	N/A battery operated	N/A battery operated	N/A battery operated	SE
Average DC current through electrodes when device is on but no pulses are being applied	User pure AC, No DC current used	User pure AC, No DC current used	User pure AC, No DC current used	User pure AC, No DC current used	SE
Number of output modes	14 programs	15 programs	Information not available	8 programs	Similar
Output channels	2 output Channels	2 output channels	2 output channels	1 output channel	SE
a. Method of current isolation	Individually isolated circuits, and transistors	Individually isolated circuits, and transistors	Individually isolated circuits, and transistors	NA	SE
Regulated Current or Regulated Voltage?	Regulated Voltage	Regulated Current	Information not available	Regulated voltage	SE

Indicator Display: On/OFF Status? Low Battery? Voltage/Current Level?	Yes, Shows On/off status Yes, Shows Low Battery Yes, shows output level 1-15	Shows On/Off Status Yes shows battery low	Shows On/Off Status	Shows On/Off Status Yes shows battery low	SE
	(1 being low 15 being high)	Shows voltage level		Shows voltage level	
Software					
firmware, microprocessor	MCU: PIC16F1937 Edition	MCU	MCU	MCU	SE
control	V1.0	Yes	NO, Battery operated	NO	
Automatic overload trip	Yes	Yes	NO, Battery Operated	Yes	
Automatic No load trip	Yes	Yes	Yes	Yes	
Automatic Shut Off	Yes	Yes, pause button	Yes (anytime)	Yes, pause button	
User Override control	Yes, pause button	60min	15min – 60min	10- 540min	
Timer Range (minutes)	15min – 60min				
Hardware and materials					
Housing construction					
material	ABS	ABS	ABS	ABS	SE
Size:	92 x 60 x 18mm	108 x 62 x 26mm	141 (L) x 60(W) X	n/a	
Weight:	0.07 kg. without battery, 0.09kg. with battery	96g with battery	18(H) mm 115 grams	25g	
Electrode Lead wires	0.07kg. With battery		115 grams		
Length	1.m		2' round self-adhering		SE
Construction	Strand		reusable Amgel based		
Materials	Copper wire PVC Coating		electrodes, FDA		
Electrode connectors	2x2mm Pin connector		approved		
510K number:	K171722	K132588			

The subject device is essentially identical to the predicate device in terms mechanism and design. The differences in number of programs, dimension and weight does not raise safety and effectiveness issues. The electrode leas wire is FDA 510(K) cleared, as the predicate devices.

Table 5.3 shows similarities and differences of output performance between our device and the predicate devices.

Table 5.3: Comparison of Output Performance

Characteristic	Subject device (K201431)	Primary Predictive Device	Reference Device (K162517)	Remarks
G.	D	(K193275)	D	GE.
Shape	Rectangular	Rectangular	Rectangular	SE
Maximum Output	17-20v +/-20%@ 500kΩ	29.7-39v +/-20%@ 500kΩ	29.6-57.6v +/-20%@ 500kΩ	SE
Voltage (V) (+/%)	48-60v +/-20%@ 2kΩ	89.1-90.6v +/-20%@ 2kΩ	80.8-86.4v +/-20%@ 2kΩ	
	95-125v +/-20%@ 10kΩ	123-125v +/-20%@ 10kΩ	108-134v +/-20%@ 10kΩ	
Maximum Output	36-40mA +/-20%@ 500Ω	59-60mA +/-20%@ 500Ω	59.2-115.2mA +/-20%@ 500Ω	SE
Current (mA) (+/- %)	24-30mA +/-20%@ 2kΩ	44-45.3mA+/-20% @ 2kΩ	33.2-48mA+/-20% @ 2kΩ	
, , , , ,	9-12.5mA +/-20%@ 10kΩ	12.3-12.5mA +/-20%@ 10kΩ	10.8-13.4mA +/-20%@ 10 kΩ	
Pulse duration† (μs)	100-200 μS @ 500Ω	150-350 μS 500Ω	100 μS	SE
Frequency (Hz) {or Rate	2-150 Hz	2-125 Hz	1.9-104.1 Hz	SE
(pps)}				
Net Charge	12-21 [μC] @ 500Ω	5.9-21 [μC] @ 500Ω	11.8-23 [μC] @ 500Ω	SE
(microcoulombs (μC) per				
pulse)				
Maximum Phase Charge	12-21 [μC] @ 500Ω	5.9-21 [μC] @ 500Ω	11.8-23 [μC] @ 500Ω	SE
(μC)				
Maximum Current	$0.16 - 0.54 \text{mA/cm2} @ 500 \Omega$	0.15 -0.72mA/cm2@500 Ω	1.64-3.26mA/cm2@500Ω	SE
density ††(mA/cm2,				
r.m.s.)				
Maximum Average	0.0002-0.0026mA/cm2	0.0002-0.0045mA/cm2	0.00004-0.00101mA/cm2	SE
Power Density††	<u>@</u> 500Ω	@500Ω	@500Ω	
(W/cm2)				
Burst Mode	Yes/No	Yes/No	n/a	
Pulses per Burst	9	15-840	n/a	SE
Bursts per Second	2	0.07-0.33	n/a	SE
Burst duration (seconds)	175 μs – 5s	3-14	n/a	SE
ON Time (seconds)	5-8	3-14	3.4-20	SE
OFF time (seconds)	5-12	2-10	1-2.5	SE

The output performances of the subject device are either within the range covered by the predicate device, or in the close proximity of the range covered by the predicate device. The subject device essentially has the same performance as that of the predicate device. Our device is essentially identical to the predicate device in terms of indications for use, design, and mechanism, between subject device and the predicate device.

The following table shows similarities and differences of the key performance between the subject device and the predicate devices. Tests were conducted following applicable procedures outlined in the internal procedures and FDA recognized consensus standards, and results met all relevant requirements in the test standards, and are comparable to the predicate device in performance.

Table 5.4: Comparison of Device Performance

Description	Subject Device	Primary Predicate Device (K193275)	Reference Device (K092990)	Comparison
Biocompatibility	Biocompatible per ISO 10993-1	Biocompatible per ISO 10993-1	Biocompatible per ISO 10993-1	SE
Electric Safety	The proposed device was tested to demonstrate compliance with IEC 60601-1	Compliance with IEC 60601-1	Compliance with IEC 60601-1	SE
EMC	The proposed device was tested to demonstrate compliance with IEC 60601-1-2	Compliance with IEC 60601-1-2	Compliance with IEC 60601-1-2	SE
Performance Standards	The proposed device was tested to demonstrate compliance with IEC 60601-2-10	Compliance with IEC 60601-2-10	Compliance with IEC 60601-2-10	SE

The above table shows that the performance is either same or very similar between the subject and predicate device. The subject device is as safe and effective, and its performance meets the requirements of its pre-defined acceptance criteria and intended uses.

5.10 Substantial Equivalence Conclusion

Based on the comparison of intended use, design, and performance, "OGYILI TENS/NMES" manufactured by "Dongguan Tutamen Metalwork Co., LTD." is substantial equivalent to its predicate devices.